BUSINESS
    MSD Japan Suffers 7% Sales Dip on Repeated Keytruda Re-Pricing, Urges Policy Rethink
    April 21, 2021
    Stellar sales performances are at times a mixed bag of good and bad for drug makers operating in Japan. This holds so true for US Merck’s I/O star Keytruda (pembrolizumab), which was hit by two…

    LATEST

    EFPIA Issues Proposals for Japanese CEA System, Says “Cannot Accept” Expansion without Corrective Steps
    April 21, 2021
    After a series of first decisions made around Japan’s cost-effectiveness assessment (CEA) scheme, EFPIA issued a statement on April 20 that sorted out issues identified with experiences of its member firms and recommended corrective measures…
    Vaccine Industry Group Calls for Govt’s Control Functions for Infectious Diseases
    April 21, 2021
    The Japan Association of Vaccine Industries on April 20 urged the government to establish control tower functions to promote public-private-academic cooperation and collaborations between companies and global partners in the infectious disease arena. It also…
    Japan Officially Announces CEA-Based Prices for Kymriah/Trelegy, Effective July 1
    April 21, 2021
    Japan on April 20 officially announced new NHI prices based on cost-effectiveness assessments (CEAs) for Novartis’ CAR-T cell therapy Kymriah (tisagenlecleucel) and GlaxoSmithKline’s COPD drug Trelegy (fluticasone furoate + umeclidinium + vilanterol), which will take…

    COMMENTARY

    Japan’s First CEA-Based Price Tweaks Draw Near, April Listing Round at Earliest
    By Takashi Ohama

    The Ministry of Health, Labor and Welfare (MHLW) appears to be ready to begin post-launch drug price adjustments based on cost-effectiveness assessments (CEAs) for the first time since the system was introduced in April 2019. As price tweaks will be…

    INTERVIEW

    From Treatment to Prevention, Top Expert on AD Research, Aducanumab and Its Implications - 2
    By Yoshinori Sagehashi

    Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…

    FY2020 Drug Pricing Reform

    Japan Panel Hammers Out FY2020 Drug Pricing Reform

    Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…

    Reimbursement Listing in 2018-2019

    Japan’s First Biosimilars of Avastin, Nesp, Forteo Receive Listing

    The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…

    HTA Debates in 2018-2019

    Japan to Roll Out Cost-Effectiveness Assessment Scheme in April

    Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…

    COLUMN

    Do You Attract or Repel Winning Candidates?
    By Philip Carrigan

    After decades in recruitment, I say from experience that there’s a particular way to attract candidates to a given role. Do it right, and you’ll have talent chasing you. Get it wrong, and you’ll be left listening to the crickets…

    NEWS CATEGORY

    REGULATORY

    BUSINESS

    ORGANIZATION

    ACADEMIA